— Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., April 30, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational […]
— Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST — ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for
ROCKVILLE, Md., Aug. 29, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by
May 07, 2026 08:13 ET – Acuerdo con la FDA sobre el diseño del ensayo de Fase 3 de VCN-01 (zabilugene almadenorepvec) para el tratamiento del adenocarcinoma ductal pancreático metastásico (PDAC) – – Los datos adicionales del ensayo clínico VIRAGE de Fase 2b con VCN-01 en pacientes con PDAC metastásico, presentados en la reciente reunión
May 05, 2026 16:30 ET – Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) – – Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated
April 18, 2026 13:17 ET – Los análisis de la respuesta tumoral, los biomarcadores y los subgrupos del ensayo clínico VIRAGE de Fase 2b respaldan el mecanismo de acción inmunomediado de VCN-01 y demuestran una mejora en los resultados de los pacientes tratados con VCN-01 en múltiples subgrupos, incluidos los pacientes con metástasis hepáticas –
April 17, 2026 16:05 ET – Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases – – Data to be presented in a poster session at the American
April 17, 2026 16:05 ET – Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases – – Data to be presented in a poster session at the American
March 23, 2026 08:00 ET – Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from FDA and previously from EMA enables company to finalize protocol for pivotal Phase 3 clinical trial while pursuing strategic
March 23, 2026 13:17 ET – El éxito de la reunión con la FDA permite avanzar hacia el ensayo clínico de fase 3 propuesto del VCN-01 en combinación con gemcitabina/nab-paclitaxel para el tratamiento de primera línea del ACDP metastásico – – Los comentarios combinados de la FDA y, anteriormente, de la EMA permiten a la
